Rosengren, Annika
Edqvist, Jon
Rawshani, Araz
Sattar, Naveed
Franzén, Stefan
Adiels, Martin
Svensson, Ann-Marie
Lind, Marcus
Gudbjörnsdottir, Soffia
Funding for this research was provided by:
the Swedish Research Council ([2013-5187, 2013-4236])
The Swedish Association of Local Authorities and Regions
the Swedish State under the Agreement Concerning Research and Education of Doctors ([2015-0438])
the Swedish Heart and Lung Foundation ([2015-0438])
the Swedish Diabetes Foundation
The Swedish Diabetes Association and the Swedish Society of Diabetology
the Swedish Council for Health, Working Life and Welfare ([2013-0325])
Article History
Received: 26 April 2018
Accepted: 21 June 2018
First Online: 9 August 2018
Duality of interest
: ML has received lecture fees from Astra Zeneca, Eli Lilly and Novo Nordisk, research grants from Astra Zeneca and Novo Nordisk, and has been a consultant for MSD and Novo Nordisk, all outside the submitted work. NS reports grants and personal fees from Boehringer Ingelheim, personal fees from Janssen, Novo Nordisk and Eli Lilly and grants from AstraZeneca, all outside the submitted work. ARo, ARa, JE, SF, MA, A-MS and SG declare that there is no duality of interest associated with their contribution to this study.